Last reviewed · How we verify

Primary cholangitis — Treatment Landscape & Competitive Intelligence

Primary cholangitis (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Primary cholangitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Ocaliva OBETICHOLIC ACID Intercept Pharms Inc Farnesoid X Receptor Agonist Bile acid receptor 2016-01-01
Ocaliva Ocaliva Universitaire Ziekenhuizen KU Leuven G-protein coupled bile acid receptor 1, Bile acid receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Intercept Pharms Inc · 1 drug in Primary cholangitis
  2. Universitaire Ziekenhuizen KU Leuven · 1 drug in Primary cholangitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Primary cholangitis:

Cite this brief

Drug Landscape (2026). Primary cholangitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/primary-cholangitis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing